分析师在收入和前景变化不一的情况下调整了对若干生物技术库存的评级。 Analysts adjusted ratings on several biotech stocks amid mixed earnings and shifting outlooks.

杰弗里斯的分析师将Next (NXGPY) 的评级从"强购"降至"持有", Analysts at Jefferies downgraded Next (NXGPY) to "hold" from "strong-buy," citing shifting outlooks without detailed reasons. 华尔街禅将NextNRG (NXXT) 升级为"持有",而HC Wainwright则以"买入"评级和5.00美元的目标开始覆盖;在Q3收入失败后,该股仍低于关键移动平均线. NextNRG (NXXT) was upgraded to "hold" by Wall Street Zen, while HC Wainwright initiated coverage with a "buy" rating and $5.00 target; the stock remains below key moving averages after missing Q3 earnings. 尽管损失大于预期,NextCure (NXTC) 获得了华尔街禅的"持有"升级,评级不一,收益高于预期;该公司继续开发癌症免疫疗法. NextCure (NXTC) received a "hold" upgrade from Wall Street Zen, with mixed ratings and better-than-expected earnings despite a wider-than-expected loss; the company continues developing cancer immunotherapies.